Infeksi intra-abdominal akibat luka tembus pada dinding abdomen atau pecahnya saluran cema merupakan keadaan akut yang memerlukan tindakan bedah serta antibiotika yang tepat. Isepamisin adalah suatu aminoglikosid yang efektif untuk menghambat berbagai kuman Gram negatif penyebab infeksi inta-abdominal. Tujuan penelitian ini adalah untuk mengetahui efektivitas dan keamanan isepamisin (15 mg/kgBB IV sekali sehari) dibandingknn dengan amikasin (7.5 mg/kg BB IV dua kali sehari). Pada kedua rejimen ini ditambahkan metronidazol. Penelitian ini menggunakan desain acak, terbuka, dan paralel, dengan menggunalcan rasio jumlah subyek isepamisin:amikasin = 2:1. Dari 50 pasien yang diikutsertakan, 27 pasien memenuhi syarat untuk digolongkan ke dalam populasi keamanan dan efektivitas, sedangkan 46 pasien digolongkan ke dalam populasi intent-to-treat. Dari populasi keamanan dan efektivitas, angka keberhasilan klinik pengobatan kelompok isepamisin dan amikasin tidak berbeda bermakna (masing-masing 95Vo dan I00Vo). Dari populasi intent-to-treat, angka keberhasilan klinik pengobatan kelompok isepamisin dan amiknsin juga tidak berbeda bermakna (masing-masing 97Vo dan 100Vo). Angka eliminasi bakteriologik kedua kelompok tidak berbeda bermakna, baik pada populasi efektivitas dan keamanan (masing-masing 95Vo dan 1007o) maupun pada populasi intent-totreat (masing-masing 90Vo dan 93Vo). Streptokokus dan stafilokokus merupakan patogen yang paling sering (40Vo) diisolasi dari pus pada penelitian ini, sedangkan Acinelobacter anitratus merupakttn kuman yang tersering (55Vo) diasingkan dari darah penderita.
Intra-abdominal infections are life-threatening conditions due to contamination of the abdominal cavity by the gut microflora. The most prominent aerobic pathogens causing these infections are Escherichia coli, Klebsiella sp , Enterobacter, and proteus spp.l Bacteroides fragilis, an anaerobic normal flora in the lumen of the gut, is also likely en-countered as a causative pathogen in such infections, Therefore antibiotic combinations used to treat intra-abdominal infections should cover both aerobic and anaerobic pathogens.2 Isepamicin is an aminoglycoside with a good activity against aminoglycoside-resistant pathogens. It is not modified by the 2"-aminoglycoside adenylyl-transferase or aminoglycoside acetyltransferases that inactitivate gentamicin. [t is also less affected by the 6'-amino-acetyltransferase-I that inactivates amikacin 3. A previous report from Mexico indicated that isepamicin was as effective as amikacin, in combination with metronidazole, in the treatment of intraabdominal infection a.
The objective of the present study is to compare the efficacy and safety of isepamicin plus metronidazole and amikacin plus metronidazole in patients hospitalized with intra-abdominal infections.
METHODS

Study sites
The study was carried out during 1997-199g (Table 2) . For both populations, the differences were not statistically significant. Fifty-three and 9 strains of microorganisms were isolated from pus and blood, respectively (Table 4) .
Streptococci (15) and Staphylococcus epidermidis (6) were the most commonly isolated pathogens from pus in the present study. These Gram positive cocci constituted 39. (Table 6) . Increased creatinine blood level for more than 3 times normal value was observed in one patient on amikacin. showed approximately the same satisfactory outcome.
In the intent-to-treat group bacteriological elimination rates were 90.3Vo and 93.3Vo, respectively. In the efficacy population the figures were 95Va and l00Vo, respectively. None of these differences. was statistically significant.
